AcquisitionsJul 6, 2026, 09:17 AM
Liminatus Pharma Completes Acquisition of InnocsAI LLC
AI Summary
Liminatus Pharma, Inc. announced the completion of its acquisition of InnocsAI LLC on July 2, 2026. The merger consideration included the issuance of 11,188,729 shares of common stock and 158,881.1271 shares of newly designated Series A Non-Voting Convertible Preferred Stock to InnocsAI's former members. The Series A Preferred Stock is convertible into common stock, subject to future stockholder approval, and the merger agreement was amended to facilitate closing prior to obtaining such approval.
Key Highlights
- Liminatus Pharma completed the acquisition of InnocsAI LLC on July 2, 2026.
- Issued 11,188,729 shares of common stock to former InnocsAI members.
- Issued 158,881.1271 shares of Series A Preferred Stock as merger consideration.
- Each Series A Preferred Stock is convertible into 10,000 shares of common stock.
- Conversion of Series A Preferred Stock requires future stockholder approval.
- Amended merger agreement on June 29, 2026, to allow closing prior to stockholder approval.
- Key InnocsAI employees entered into a 2-year non-compete and non-solicitation agreement.
Price Impact
More from LIMN